TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7703597

Group type: EXPERIMENTAL
Intervention: Intravenous nutrition (IVN) for 10 days
Number of subjects: 7
Study: 3316118

Group type: EXPERIMENTAL
Intervention: Vitamin E (500 IU/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 30653863

Group type: EXPERIMENTAL
Intervention: Aerobic training (exercise group)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Inactive sedentary group (control group)
Number of subjects: 67
Study: 28433443

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injections
Number of subjects: 101

Group type: COMPARATOR
Intervention: Arthroscopic lateral release
Number of subjects: 101
Study: 23875573

Group type: EXPERIMENTAL
Intervention: Frequent pitches in an identification task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infrequent pitches presented in isolation
Number of subjects: 0
Study: 22134392

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring (HBPM)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 136
Study: 20658802

Group type: EXPERIMENTAL
Intervention: Nia (culturally informed, empowerment‐focused psychoeducational group intervention)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Nia
Number of subjects: 208

Group type: COMPARATOR
Intervention: TAU (treatment as usual)
Number of subjects: 208
Study: 17587720

Group type: EXPERIMENTAL
Intervention: Amiodarone (400 mg/day) 2 months before PTMV
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg/day) after cardioversion
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: PTMV
Number of subjects: 23
Study: 15961764

Group type: EXPERIMENTAL
Intervention: IFN-alpha-2a plus 13-CRA
Number of subjects: 320

Group type: COMPARATOR
Intervention: IFN-alpha-2a alone
Number of subjects: 320
Study: 11948889

Group type: EXPERIMENTAL
Intervention: Gradient Field Transform (GFT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Minimal Cost Algorithm (MCA)
Number of subjects: 125
Study: 9579811

Group type: EXPERIMENTAL
Intervention: PGI/MN II monoclonal antibodies
Number of subjects: 142

Group type: COMPARATOR
Intervention: D8/17 monoclonal antibodies
Number of subjects: 142
Study: 7607786

Group type: EXPERIMENTAL
Intervention: 5-ASA at 2.4 g/day in a delayed-release formulation (Eudragit-S-coated Mesaline)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Non-specific therapy (Control group)
Number of subjects: 66
Study: 3049227

Group type: EXPERIMENTAL
Intervention: Linkage analysis using various selection rules on pedigree subsets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selection of recessive-appearing pedigrees for linkage analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Including information on unaffected second-degree relatives in linkage studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linkage analysis using three autosomal dominant models and three autosomal recessive models
Number of subjects: 0
Study: 31678223

Group type: EXPERIMENTAL
Intervention: Low-Intensity Treadmill Training (2×/wk for 6 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: High-Intensity Treadmill Training (10×/wk for 6 weeks)
Number of subjects: 19
Study: 29622600

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibition
Number of subjects: 4853
Study: 28365033

Group type: EXPERIMENTAL
Intervention: Lorcaserin in elderly patients
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lorcaserin in patients with renal impairment
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Lorcaserin in patients with hepatic impairment
Number of subjects: 3
Study: 26437535

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 26

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 26
Study: 24095299

Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol 145 mg/m(2) every 14 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol 145 mg/m(2) every 21 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study: 21165807

Group type: EXPERIMENTAL
Intervention: High-impact step aerobic exercise (SA, n=15)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Moderate-intensity lower body strength training (ST, n=16)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-exercise control (CON, n=20)
Number of subjects: 51
Study: 18510609

Group type: EXPERIMENTAL
Intervention: Office-based IFOBT
Number of subjects: 640

Group type: COMPARATOR
Intervention: M2-PK
Number of subjects: 640
Study: 16594854

Group type: EXPERIMENTAL
Intervention: Individual genetic risk counseling
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Group psychosocial counseling
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 211
Study: 14570527

Group type: EXPERIMENTAL
Intervention: Group education intervention (GE)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Group education‐plus‐discussion intervention (GED)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study: 10919899

Group type: EXPERIMENTAL
Intervention: Valaciclovir (500 mg, three times daily)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Acyclovir (800 mg, five times daily)
Number of subjects: 110
Study: 8761985

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (10%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (20%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (40%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nitrous oxide (0%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (0%, 10%, 20%, 30%, 40%)
Number of subjects: 10
Study: 1451073

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated radiation therapy (AHRT) at 48.0 Gy
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionated radiation therapy (AHRT) at 54.4 Gy
Number of subjects: 304

Group type: COMPARATOR
Intervention: Standard radiation therapy (RT) and bis-chloroethyl nitrosourea (BCNU) for patients 60 years or older
Number of subjects: 304
Study: 6731323

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1375

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1375
Study: 30591391

Group type: EXPERIMENTAL
Intervention: Photobiomodulation with low-level laser therapy (LLLT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no LLLT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 29464587

Group type: EXPERIMENTAL
Intervention: 20 mg/day vonoprazan
Number of subjects: 149

Group type: COMPARATOR
Intervention: 30 mg/day lansoprazole
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Delayed bleeding
Number of subjects: 149
Study: 27306921

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (specific dosage and duration not available)
Number of subjects: 0
Study: 25281675

Group type: EXPERIMENTAL
Intervention: CAD/CAM technology
Number of subjects: 76

Group type: COMPARATOR
Intervention: Traditional preparation methods
Number of subjects: 76

Group type: COMPARATOR
Intervention: No CAD/CAM technology
Number of subjects: 76
Study: 22706944

Group type: EXPERIMENTAL
Intervention: HGI (High Glycaemic Index) meal (GI: 80)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: LGI (Low Glycaemic Index) meal (GI: 44)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Both HGI and LGI meals
Number of subjects: 9
Study: 20920044

Group type: EXPERIMENTAL
Intervention: sitagliptin
Number of subjects: 37

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: intensive insulin therapy (IIT)
Number of subjects: 37
Study: 18040529

Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 21
Study: 16120075

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study: 12390610

Group type: EXPERIMENTAL
Intervention: Acupuncture (group A, n = 80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Flunarizine (group F, n = 80)
Number of subjects: 160
Study: 10192649

Group type: EXPERIMENTAL
Intervention: >= 1 drink/week
Number of subjects: 21041

Group type: COMPARATOR
Intervention: < 1 drink/week
Number of subjects: 21041

Group type: EXPERIMENTAL
Intervention: 1 drink/week
Number of subjects: 21041

Group type: EXPERIMENTAL
Intervention: 2-4 drinks/week
Number of subjects: 21041

Group type: EXPERIMENTAL
Intervention: 5-6 drinks/week
Number of subjects: 21041

Group type: EXPERIMENTAL
Intervention: >= 1 drink/day
Number of subjects: 21041
Study: 7721268

Group type: EXPERIMENTAL
Intervention: Measurement of bone mass by dual energy X‐ray absorptiometry of the hip, spine or forearm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New markers specific for bone formation and bone resorption
Number of subjects: 0
Study: 2287555

Group type: EXPERIMENTAL
Intervention: Tourniquet inflation at 5 minutes after cefazolin administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tourniquet inflation at 2 minutes after cefazolin administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tourniquet inflation at 1 minute after cefazolin administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of soft tissue penetration between 5 and 1 minute
Number of subjects: 0
Study: 6973989

Group type: EXPERIMENTAL
Intervention: 50 mg fluproquazone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 100 mg fluproquazone
Number of subjects: 59
Study: 31170178

Group type: EXPERIMENTAL
Intervention: RT-real-time PCR testing for enterovirus
Number of subjects: 14928

Group type: EXPERIMENTAL
Intervention: Serotype distribution of enteroviruses
Number of subjects: 14928

Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis of enterovirus serotypes
Number of subjects: 14928

Group type: EXPERIMENTAL
Intervention: Epidemic incidence rates
Number of subjects: 14928

Group type: EXPERIMENTAL
Intervention: Epidemic peaks
Number of subjects: 14928
Study: 28118533

Group type: EXPERIMENTAL
Intervention: Subcutaneous belimumab 200 mg weekly
Number of subjects: 836

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 836
Study: 25082346

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg QD
Number of subjects: 46
Study: 23406311

Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate drinks and postoperative polymeric supplement drinks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 120
Study: 21839898

Group type: EXPERIMENTAL
Intervention: SFC (salmeterol/fluticasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MON (montelukast)
Number of subjects: 0
Study: 19703126

Group type: EXPERIMENTAL
Intervention: DTPa5 vaccination
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: DTPa5 re-vaccination at 4, 5, and 6 years of age
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: DTPa5 or DTPwc primed children with verified pertussis infection
Number of subjects: 542

Group type: COMPARATOR
Intervention: DTPa2 or DT group (not primed with fimbriae)
Number of subjects: 542

Group type: COMPARATOR
Intervention: DTPa2 and DTPa3 vaccines
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: IgG anti-Fim2/3 levels > or =5 EU/ml
Number of subjects: 542
Study: 16421426

Group type: EXPERIMENTAL
Intervention: NHL-BFM95 (no prophylactic cranial radiotherapy)
Number of subjects: 156

Group type: COMPARATOR
Intervention: NHL-BFM90/86 (with prophylactic cranial radiotherapy)
Number of subjects: 156
Study: 15313300

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (balanced saline solution)
Number of subjects: 90
Study: 11151742

Group type: EXPERIMENTAL
Intervention: Caffeine 2.1 mg kg‐1 body weight (low dose)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Caffeine 4.3 mg kg‐1 body weight (medium dose)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Caffeine 8.6 mg kg‐1 body weight (high dose)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9296412

Group type: EXPERIMENTAL
Intervention: Light wand intubation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rigid laryngoscopy
Number of subjects: 40
Study: 8160559

Group type: EXPERIMENTAL
Intervention: Not applicable, as this is a review of clinical trials and does not specify a particular intervention.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not applicable, as this is a review of clinical trials and does not specify a particular control.
Number of subjects: 100
Study: 2871783

Group type: EXPERIMENTAL
Intervention: Bevantolol 200 to 400 mg/day
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 31474282

Group type: EXPERIMENTAL
Intervention: Self-affirmation condition (writing essays about personally important values)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control condition (writing essays about personally unimportant values)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Self-affirmation condition
Number of subjects: 163
Study: 29210953

Group type: EXPERIMENTAL
Intervention: Citrulline Malate (CM) 8 g
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study: 26437670

Group type: EXPERIMENTAL
Intervention: Upright neonatal resuscitator
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard Laerdal neonatal resuscitator
Number of subjects: 87
Study: 24095257

Group type: EXPERIMENTAL
Intervention: Active tDCS (1.5 mA for 20 min over the right dlPFC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 42
Study: 22998687

Group type: EXPERIMENTAL
Intervention: Esomeprazole (ESO) treatment for 5 years
Number of subjects: 554

Group type: COMPARATOR
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 554
Study: 20951306

Group type: EXPERIMENTAL
Intervention: WMTA at pH 7.4
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: WMTA at pH 4.4
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Aureoseal at pH 7.4
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Aureoseal at pH 4.4
Number of subjects: 64
Study: 17435678

Group type: EXPERIMENTAL
Intervention: Toxoplasma-infected men
Number of subjects: 89

Group type: COMPARATOR
Intervention: Non-infected men (control group)
Number of subjects: 89
Study: 15905191

Group type: EXPERIMENTAL
Intervention: Mercaptopurine (MP) alone
Number of subjects: 82

Group type: COMPARATOR
Intervention: Methotrexate plus Mercaptopurine (MTX + MP)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Nitrobenzylmercaptopurine ribonucleoside (NBMPR) in vitro
Number of subjects: 82
Study: 14591851

Group type: EXPERIMENTAL
Intervention: malingering
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: malinger-with-warning
Number of subjects: 60

Group type: COMPARATOR
Intervention: control
Number of subjects: 60
Study: 9457819

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy (HFX RT) with a thoracic spinal cord dose of 50.4 Gy given via 1.2 Gy b.i.d. fractionation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Concurrent chemotherapy (CHT)
Number of subjects: 300
Study: 7618725

Group type: EXPERIMENTAL
Intervention: Epidural lidocaine (2% lidocaine)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 10
Study: 2612558

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil 360 mg at 22.00 h
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sustained-release verapamil 360 mg at 08.00 h
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil 360 mg at night (24.00 h-06.00 h)
Number of subjects: 10
Study: 589349

Group type: EXPERIMENTAL
Intervention: Medical teams for psychiatric assessment
Number of subjects: 276

Group type: COMPARATOR
Intervention: Psychiatrists for psychiatric assessment
Number of subjects: 276
Study: 30771362

Group type: EXPERIMENTAL
Intervention: Enhanced NCMP letters
Number of subjects: 2642

Group type: COMPARATOR
Intervention: Control letters
Number of subjects: 2642

Group type: EXPERIMENTAL
Intervention: Self-report variables
Number of subjects: 2642
Study: 28981543

Group type: EXPERIMENTAL
Intervention: Daily 4% chlorhexidine care
Number of subjects: 89

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 89
Study: 25939018

Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy (CPT-C)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Group Present-Centered Therapy (PCT)
Number of subjects: 108
Study: 23872500

Group type: EXPERIMENTAL
Intervention: High-fructose diet
Number of subjects: 32

Group type: COMPARATOR
Intervention: High-glucose diet
Number of subjects: 32
Study: 21742012

Group type: EXPERIMENTAL
Intervention: Nicotine (4mg) with ketamine (0.04mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo gum with ketamine (0.04mg/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nicotine (4mg) with placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo gum with placebo
Number of subjects: 40
Study: 17901240

Group type: EXPERIMENTAL
Intervention: EX‐C (exercise with a thermal clamp at 24 degrees C)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: EX‐H (exercise-induced heating at water temperature 36 degrees C)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PA‐H (passive heating at 38.5 degrees C)
Number of subjects: 13

Group type: COMPARATOR
Intervention: CON (control at 35 degrees C)
Number of subjects: 13
Study: 16261517

Group type: EXPERIMENTAL
Intervention: Meta050 (440 mg three times a day for 4 weeks, then 880 mg twice a day for 4 weeks)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Meta050
Number of subjects: 54
Study: 12072677

Group type: EXPERIMENTAL
Intervention: Coupled plasma filtration adsorption plus hemodialysis (treatment A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous venovenous hemodiafiltration (treatment B)
Number of subjects: 10
Study: 10190722

Group type: EXPERIMENTAL
Intervention: UDCA treatment
Number of subjects: 103
Study: 7797061

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 0
Study: 2224694

Group type: EXPERIMENTAL
Intervention: High-dose zidovudine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose zidovudine therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 0
Study: 426553

Group type: EXPERIMENTAL
Intervention: 6000 rads plus 5‐FU
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 4000 rads plus 5‐FU
Number of subjects: 106

Group type: COMPARATOR
Intervention: 6000 rads alone
Number of subjects: 106
Study: 31705570

Group type: EXPERIMENTAL
Intervention: Cytarabine and daunorubicin (7 + 3)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Clofarabine
Number of subjects: 32
Study: 27393080

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/day orally) with EE/LNG
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/day orally) with EE/DRSP
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo with EE/LNG
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo with EE/DRSP
Number of subjects: 81
Study: 25976296

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No prophylactic cranial irradiation (no PCI)
Number of subjects: 51
Study: 23111852

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Combination therapy with fosinopril and pravastatin
Number of subjects: 655

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 655
Study: 21797983

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (online discussion group)
Number of subjects: 78
Study: 19564523

Group type: EXPERIMENTAL
Intervention: PSA-detected cancers
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: PSA-detected cancers with Gleason score <7
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: PSA-detected cancers with Gleason score 7 or more
Number of subjects: 3535

Group type: EXPERIMENTAL
Intervention: Interaction between detection mode and Gleason score
Number of subjects: 3535
Study: 16760859

Group type: EXPERIMENTAL
Intervention: Powerlink Bifurcated endovascular graft
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control (open AAA repair)
Number of subjects: 258
Study: 16433156

Group type: EXPERIMENTAL
Intervention: Microsurgery (laparotomy)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 224
Study: 12039422

Group type: EXPERIMENTAL
Intervention: Riluzole 50mg capsules orally, taken twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 20
Study: 10213062

Group type: EXPERIMENTAL
Intervention: Transversely split velum (TS) flaps
Number of subjects: 42

Group type: COMPARATOR
Intervention: Midline split (MS) flaps
Number of subjects: 42
Study: 7781667

Group type: EXPERIMENTAL
Intervention: Insulin treatment in 108 NIDDM patients with Lp(a) concentration < 300 mgL-1
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Insulin treatment in subjects with elevated Lp(a) concentrations (> 300 mgL-1)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 145
Study: 2202462

Group type: EXPERIMENTAL
Intervention: Total body irradiation followed by 12 courses of high dose cytosine arabinoside (Ara‐C)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cyclophosphamide-containing preparative regimens
Number of subjects: 68
Study: 38705

Group type: EXPERIMENTAL
Intervention: Intravenous dose of 10 mg of metopimazine, three times D-1, for two days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Identically administered placebo
Number of subjects: 84
Study: 31009289

Group type: EXPERIMENTAL
Intervention: Combination of 2 mg tolterodine and 9 mg pilocarpine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tolterodine monotherapy (2 mg twice daily)
Number of subjects: 100
Study: 27761943

Group type: EXPERIMENTAL
Intervention: Adaptive working memory training (WMT)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Nonadaptive working memory training (WMT)
Number of subjects: 201